Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

The acquisition of Inozyme Pharma Inc by BioMarin Pharmaceutical was formally completed in July, marking a significant consolidation in the rare disease therapeutics sector. The transaction, valued at $270 million, provided shareholders with a final payout of $4.00 per share. All attention has now shifted to the future development of the flagship asset, BMN 401.

BioMarin Pharmaceutical acquired all outstanding shares of Inozyme Pharma at a fixed price of $4.00 per share. The strategic nature of this move was recently underscored during BioMarin’s presentation at the Cantor Global Healthcare Conference. Company executives confirmed that the continued advancement of BMN 401?previously known as INZ-701?is now a central priority.

Gregory Friberg, Executive Vice President at BioMarin, characterized the therapy as a “first-in-class and Read more...